Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etigilimab - Mereo BioPharma

Next Previous
X
Search
Drug Profile

Etigilimab - Mereo BioPharma

Alternative Names: Anti-TIGIT monoclonal antibody; Anti-TIGIT monoclonal antibody - OncoMed; MPH-313; OMP-313M32

Latest Information Update: 15 May 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OncoMed Pharmaceuticals
  • Developer Mereo BioPharma; OncoMed Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 23 Oct 2023 Etigilimab - Mereo BioPharma is available for licensing as of 23 Oct 2023. http://sntpseditorial/adis2000www/
  • 21 Sep 2023 Mereo BioPharma completes the Ib/II ACTIVATE basket trial in locally advanced or metastatic solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA and UK (IV) (NCT04761198)
  • 30 Jun 2023 MD Anderson Cancer Center initiates phase-Ib/II trial for Ovarian cancer (Combination therapy, recurrent, Second-line therapy or greater) in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top